Skip to main content
Image of medicine for the treatment of drug resistant tuberculosis (DR-TB). The left hand contains pills from the recently approved BPaLM 6-month shorter regimen treatment and the right hand contains pills from the longer 18 months regimen treatment. Following the validation of shorter regimen by WHO, MSF started supporting the Ministry of Health in implementing shorter regimen for patients affected by DR-TB since 2022 in Sierra Leone. Depending on individual patients’ diagnostic and clinical situation treatment regimens are initiated. Shorter regimens are often preferred by patients and medical professionals as longer treatment can be physically and mentally harder to adhere to.

Antimicrobial resistance

A person holds medicine for the treatment of drug-resistant tuberculosis (DR-TB) in his hands. Sierra Leone, 14 December 2023.
© MSF/Ammar Obeidat

What happens when drugs stop working?

A true global health emergency, antimicrobial resistance threatens to make common infections increasingly difficult to treat and routine medical procedures increasingly risky.

Bacteria, viruses, parasites and fungi are constantly changing to ensure their survival. Some have adapted so well to medical treatment that drugs commonly used to prevent or kill them are no longer effective. These microorganisms can cause drug-resistant infections. Their ability to survive medicines used against them is called antimicrobial resistance (AMR). Antibiotic resistance (ABR) specifically refers to this phenomenon in bacterial pathogens, for which antibiotics are the most common and important drugs available for treatment.

Quick facts

This three-part series examines the medical breakthroughs that reshaped MSF's approach to care, and the innovations still urgently needed to fight three major health threats affecting the communities where MSF teams work: cholera, malnutrition, and antimicrobial resistance.
This follows a previous four-part series addressing pediatric tuberculosis, sickle cell disease, diabetes, and oncology.
video

(r)evolution(s) / AMR (ENG)

Revolutions in antimicrobial resistance

4.71 million deaths were associated with antibiotic resistance in 2021 alone. Yet in sub-Saharan Africa, just 1 per cent of labs have bacteriology capacity.

We know what AMR needs: funding, skilled human resources, capacity building, and political will that is proportionate to the urgency.

GEORGE ONDIJO IS A LAB TECHNICIAN AT NDIWAH HOSPITAL IN HOMA BAY COUNTY. HE IS IN CHARGE OF SPUTUM COLLECTION FOR TUBERCULOSIS DIAGNOSIS. THE USE OF MASK IS MANDATORY TO AVOID CONTAGION.

Medical Resource

MSF Field Research

We produce important research based on our field experience. So far, we have published articles in over 100 peer-reviewed journals. These articles have often changed clinical practice and have been used for humanitarian advocacy. All of these articles can be found on our dedicated Field Research website.

Visit site